Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brainsway ( (BWAY) ) has issued an announcement.
On August 21, 2025, BrainsWay Ltd. announced a strategic investment in Neurolief Ltd., marking its entry into the market for at-home mental health therapies. This $5 million convertible loan, with options for further funding, aims to expand BrainsWay’s total addressable market by leveraging Neurolief’s innovative Proliv™Rx device, pending FDA approval, which offers treatment for major depressive disorder outside of clinical settings. This collaboration is expected to enhance BrainsWay’s market presence and provide new treatment options for patients who struggle to access traditional clinics.
The most recent analyst rating on (BWAY) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s overall stock score is driven by its strong financial performance and positive earnings call, highlighting significant revenue growth and strategic investments. However, the high valuation and technical indicators suggesting overbought conditions temper the score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, which is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS.
Average Trading Volume: 54,218
Technical Sentiment Signal: Buy
Current Market Cap: $280.4M
See more insights into BWAY stock on TipRanks’ Stock Analysis page.